<DOC>
	<DOCNO>NCT02238314</DOCNO>
	<brief_summary>The primary objective evaluate antiviral activity safety two regimen tipranavir ( 500 mg BID 1000 mg BID ) plus ritonavir ( 100 mg BID ) administer combination 1 new nucleoside reverse transcriptase inhibitor ( NRTI ) + efavirenz multiple protease-inhibitor-experienced HIV-1 positive patient .</brief_summary>
	<brief_title>Exploratory Study Tipranavir Ritonavir Multiple Protease Inhibitor-experienced HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Multiple ( two ) PIexperience . Eligible patient must exposure least two antiretroviral regimen contain single protease inhibitor regimen contain dual protease inhibitor In investigator 's opinion , patient adhere PIcontaining regimen Exposure ≥ 3 month current PI therapy Exposure ≥ 4 month prior PI therapy single PIcontaining regimens Stable PIcontaining regimen least 2 month prior study entry HIV1RNA ≥ 5,000 copies/mL Cluster differentiation ( CD ) 4+ cell count ≥ 50 cells/mm**3 At least one new NRTI option available Age ≥ 13 year Acceptable screen laboratory value indicate adequate baseline organ function time screen . Laboratory value consider acceptable severity ≤ Grade 1 ( AIDS Clinical Trial Group ( ACTG ) Grading Scale ) . Stable Grade 2 abnormality permit value demonstrate document least ≥ 2 month . Acceptable medical history , physical examination , electrocardiogram , chest Xray prior entry treatment phase study Agreement use barrier contraceptive method birth control least 30 day prior study drug administration , study , 30 day end study Ability swallow numerous tablet capsule without difficulty Ability understand provide inform consent . Minors require approval parent legal guardian Prior exposure , define &gt; 7 treatment day , nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) include , limited : nevirapine , efavirenz , delavirdine , atevirdine , MKC442 , loviride , HBY097 Clinically significant active acute ( onset within month previous study entry ) medical problem , include follow : opportunistic infection , active cryptococcosis , Pneumocystis carinii pneumonia , herpes zoster , histoplasmosis , cytomegalovirus nonopportunistic disease , include , limited , progressive multifocal leukoencephalopathy , lymphoma , malignancy require systemic therapy Prior exposure ( &gt; 7 day ) tipranavir History clinically significant nervous system muscle disease , seizure disorder , psychiatric disorder might impair adherence protocol Taking know P450 3A enzymeinducing drug within 30 day study entry include follow : rifabutin , rifampin , carbamazepine , dexamethasone , phenobarbital , phenytoin , sulfadimidine , sulfinpyrazone , troleandomycin Hypersensitivity tipranavir and/or ritonavir Use interferon , interleukin , HIV vaccine , active immunization within 30 day prior study entry Taking investigational medication exception adefovir dipivoxil ( Preveon™ ) amprenavir ( Agenerase™ ) within 30 day study entry Pregnancy lactation ( serum βhuman chorionic gonadotrophin test negative within 14 day study entry ) Evidence active substance abuse , investigator 's opinion , could affect compliance protocol In investigator 's judgment , inability comply protocol requirement reason specify</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>